Application of catalpol in promoting the differentiation of neural stem cells into oligodendrocytes

A technology of oligodendrocytes and neural stem cells, applied in the field of stem cell therapy, can solve the problems of unclear regulatory mechanism, lack of control of NSCs differentiation and growth, and unclear NSCs differentiation conditions, etc., to achieve drug concentration, real-time observation, The effect of saving experiment time

Active Publication Date: 2021-06-25
FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still many difficulties in the clinical application of NSCs in the current clinical treatment, due to the unclear differentiation conditions of NSCs, unclear regulatory mechanisms, lack of methods to control the differentiation and growth of NSCs after transplantation, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of catalpol in promoting the differentiation of neural stem cells into oligodendrocytes
  • Application of catalpol in promoting the differentiation of neural stem cells into oligodendrocytes
  • Application of catalpol in promoting the differentiation of neural stem cells into oligodendrocytes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Application of catalpol in promoting the differentiation of NSCs into oligodendrocytes.

[0033] 1 Design and fabrication of microfluidic chip

[0034] 1) For the study of the application of catalpol in promoting the differentiation of NSCs into oligodendrocytes, the schematic diagram of the microfluidic chip device used is as follows figure 1 shown. The whole device is composed of an upstream concentration gradient generator 1 and a downstream cell culture module 2 . Due to the ability to perform integrated operations in the chip (gradient concentration generation, stimulation and cell seeding, culturing, etc.), multiple cellular responses stimulated by different drug concentrations can be recorded simultaneously. The concentration gradient generator 1 includes a chip inlet 11 and a concentration gradient dilution channel 12; the height and width of the channel are 300 μm. The cell culture module 2 includes an open chamber 21 (3×4 array) downstream of the chip, a co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention discloses the application of catalpol in promoting the differentiation of neural stem cells to oligodendrocytes, specifically using a drug concentration gradient microfluidic chip to evaluate the effect of different concentrations of natural active drug catalpol on the differentiation of NSCs to oligodendrocytes. effect. The results showed that catalpol had no toxic effect on NSCs at a concentration lower than 3 mg / mL, and catalpol could significantly promote the differentiation of NSCs into oligodendrocytes. This system provides a platform for in vitro research on the mechanism of catalpol, an active ingredient of traditional Chinese medicine, on the differentiation of NSCs oligodendrocytes. The promoting effect of catalpol, an active ingredient of traditional Chinese medicine provided by the invention, on the differentiation of NSCs oligodendrocytes provides a basis and feasible technical support for NSCs replacement therapy for central nervous system demyelinating diseases in the preclinical stage.

Description

technical field [0001] The invention belongs to the evaluation and screening of related drugs in the field of stem cell therapy, and specifically relates to the application of catalpol in promoting the differentiation of neural stem cells into oligodendrocytes. Background technique [0002] Demyelinating diseases of the central nervous system are a group of diseases in which the central nervous system is dominated by extensive primary demyelination. The disease is caused by damage or developmental disorders of oligodendrocytes leading to damage or loss of myelin sheath, which affects the conduction of nerve impulses and makes nerve dysfunction. Oligodendrocytes, as the cells necessary for the formation of myelin in the central nervous system, can maintain the normal function and structure of the nervous system, and can also provide nerve growth factors and nutritional factors for the central nervous system. At present, most demyelinating diseases can only be treated symptom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/079C12M3/00C12M1/00
CPCC12M23/16C12N5/0622C12N2500/35C12N2506/08
Inventor 刘晶王亚辰马静云王亮
Owner FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap